<DOC>
	<DOCNO>NCT01237769</DOCNO>
	<brief_summary>In recent year emphasis give investigate role vitamin D area beyond bone metabolism maintenance calcium homeostasis . Thus , vitamin D deficiency associate risk factor occurrence cardiovascular disease well overall mortality.In addition , indication large proportion population ( 50 % ) vitamin D deficient . The measurement vitamin 25 ( OH ) D3 level best way estimate vitamin D actual reserve . It worth mention elevated level parathyroid hormone ( PTH ) [ 5 ] reduce level 1,25 ( OH ) 2 vitamin D3 ( calcitriol also associate cardiovascular disease . The metabolic syndrome sum risk factor cardiovascular disease find approximately 25 % Greek population.There lot data link low vitamin D level metabolic syndrome whole well individual characteristic . Specifically , vitamin D deficiency associate increase incidence hypertension , dyslipidemia , obesity , inflammation dysglycemia . Many study explore effect give vitamin D supplement risk factor associate metabolic syndrome cardiovascular disease . The result study conflict may partially due different dos vitamin D use . The form vitamin D commonly use study cholecalciferol ( vitamin D3 . Aim study : Determination effect cholecalciferol ( VitD3 ) ( 2200 IU/day ) metabolic parameter patient metabolic syndrome . Endpoints : The primary endpoint change metabolic syndrome parameter 3 month start treatment : - Waist circumference - Blood pressure - Levels fast serum triglyceride - Levels high-density lipoprotein cholesterol ( HDL-C ) - Levels fast serum glucose . The secondary endpoint include change : - The level low-density lipoprotein cholesterol ( LDL-C ) non-HDL-C - Subfractions LDL-C [ average particle size LDL-C , level small dense ( sd ) LDL-C ] - Subfractions HDL-C ( level small large particle HDL-C ) - The activity level Lp-PLA2 ( lipoprotein-associated phospholipase A2 ) - The level serum apolipoprotein AI , A-II , AV , B , E , C-II , C-III lipoprotein ( Lp ) ( ) - The activity paraoxonase-1 ( PON1 ) - The concentration pre-beta1-HDL - The level hs-CRP ( high sensitivity C-reactive protein ) - Oxidative stress measure level 8-isoprostane blood urine oxidize LDL ( oxLDL ) - Adipokine level ( leptin , adiponectin , visfatin ) - Glucose homeostasis ( index HOMA : fasting insulin X fast glucose/405 ) - The level glycosylated hemoglobin ( HbA1c ) - The level 25 ( OH ) vitamin D3 , 1,25 ( OH ) 2 vitamin D3 PTH - The level serum electrolyte ( Ca , PO4 ) activity alkaline phosphatase ( ALP ) serum . Study population : The investigator study patient metabolic syndrome ( n = 50 adult ) attend Outpatient Lipid Obesity clinic University Hospital Ioannina . Diagnosis Metabolic Syndrome base criterion National Cholesterol Education Program Adult Treatment Panel III ( NCEP-ATP III ) . All patient instruct exercise lose weight accord NCEP-ATP III diet . The participant randomize open manner one follow 2 treatment group : ) cholecalciferol ( VitD3 ) ( 2200 IU/day ) plus lifestyle measure b ) lifestyle measure . Recruitment complete within one year . The reassessment patient do 3 month start treatment .</brief_summary>
	<brief_title>Effect Vitamin D Metabolic Parameters Patients With Metabolic Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<criteria>Patients metabolic syndrome ( n = 50 adult ) attend Outpatient Lipid Obesity clinic University Hospital Ioannina . Diagnosis Metabolic Syndrome base criterion National Cholesterol Education Program Adult Treatment Panel III ( NCEPATP III ) . The study exclude patient triglyceride level &gt; 500 mg/dL , Diabetes mellitus , hypothyroidism ( TSH &gt; 5 IU/mL ) , Primary hyperparathyroidism , hypercalcemia cause , A history take formulation calcium vitamin D , Alcohol consumption &gt; 3 drink per day men &gt; 2 drink per day woman woman childbearing age take contraceptive measure . Patients hypertension may include study blood pressure &lt; 140/90 antihypertensive treatment remain constant past 3 month ( change antihypertensive medication study ) . Finally , patient receive lipidlowering medicine patient stop take less 4 week exclude study .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>vitamin D</keyword>
	<keyword>Metabolic syndrome</keyword>
	<keyword>Hypertension</keyword>
	<keyword>Dyslipidemia</keyword>
	<keyword>Dysglycemia</keyword>
	<keyword>Inflammation</keyword>
</DOC>